[Stroke prevention in atrial fibrillation -- transfer of study results to the practice].
Kiechl
Stefan
S
D000284:Administration, Oral; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications* / Q000453:epidemiology; D001384:Azetidines / Q000008:administration & dosage / Q000627:therapeutic use; D001596:Benzylamines; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D000075202:Contraindications; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015995:Prevalence; D012008:Recurrence; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology / Q000517:prevention & control*; D013997:Time Factors
D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D010975:Platelet Aggregation Inhibitors; C426686:ximelagatran; D001241:Aspirin